2016年10月12日，山东省眼科研究所所长、山东省眼科医院院长、中华医学会眼科学分会角膜病学组组长史伟云教授，受美国哈佛大学附属麻省总院华人学者联合会的邀请，在著名的麻省总医院（MGH）Bulfinch楼的Ether Dome（“乙醚厅”）就生物工程角膜研发和临床应用情况进行了演讲。Ether Dome座无虚席，来自世界各地的专家学者认真听取了史伟云教授的报告，并积极就史伟云教授的报告进行了提问，史伟云教授对专家的提问进行了细致的回答。
  史伟云教授精彩的演讲将各国专家的视角引向了蓬勃发展的中国眼科事业，此次演讲代表着我国科学家眼科自主知识产权的研究应用得到世界顶尖学府的认可。

史伟云教授在著名的麻省总医院（MGH）Bulfinch楼的Ether Dome 进行演讲

来自世界各地的眼科专家学者认真听取史伟云教授的演讲

我国约有400万角膜盲患者，但由于我国角膜供体缺乏每年实施角膜移植复明的患者不足1万人，很多角膜盲患者在黑暗中等待光明。山东省眼科医院院长史伟云教授、谢立信院士团队牵头与中国再生医学国际有限公司合作研发的全球首个生物工程角膜于2015年4月底获得国家食品药品监督管理总局颁发的医疗器械注册证书，2015年5月23日正式投产上市。作为全球首个生物工程角膜将极大地缓解我国捐献角膜奇缺的临床困境，为我国400万角膜盲患者带来复明的希望。2015年9月首例生物工程角膜临床移植在山东省眼科研究所由谢立信院士与史伟云教授联合主刀并获得成功。  
  生物工程角膜是由异种角膜经脱细胞特殊工艺的多级处理，去除了角膜中的细胞、杂蛋白、多糖等抗原，保留了天然角膜基质胶原蛋白结构及透明性，生物相容性好，生物安全性高，能与周围组织快速整合，移植角膜透明，患者视力快速恢复。这是拥有完整自主知识产权的高科技划时代产品，在国际医学界也引起了巨大的反响。同时该项目也作为史伟云教授与谢立信院士团队部分重要支撑材料获得2015年度国家科技进步二等奖。
  为了使全球首个生物工程角膜在临床应用中获得更好的临床效果，中国再生医学国际有限公司在山东省眼科医院建设了国内首个培训基地。目前全国生物工程角膜移植培训班已经完成了十余期培训，累计培训国内外角膜移植手术医生246人。

首届全国生物工程角膜移植培训班合影

全球首个生物工程角膜在临床的成功应用在世界范围内同样引起了广泛关注，在受邀前往哈佛大学分享经验前，美国著名的哥伦比亚电视台派出记者从美国专程来到山东省眼科医院就首个生物工程角膜细节情况对史伟云教授进行了专访。

美国最大的哥伦比亚广播公司（CBS）电视网记者Adrianadiaz专程来山东省眼科医院对史伟云教授进行专访

史伟云教授是我国眼科角膜病专业领军者，中华医学会角膜病学组组长，从事眼科医疗、科研和教学工作30年，是全世界极少完成角膜手术超万例的专家。他不仅在临床上造福了无数的角膜病患者，还大刀阔斧进行学术创新，持续围绕我国角膜供体匮乏和诊治技术落后两大难题，创新开展了一系列适合我国患者的诊疗技术和临床转化研究，并在全国推广应用。

Ether Dome内景

近代世界第一例麻醉下的手术在Ether Dome完成并公开演示

麻省总医院简介：
麻省总医院（MGH）建立于1811年，是美国历史最悠久的三所医院之一，也是新英格兰地区建立最早、规模最大的医院和哈佛医学院建立最早、规模最大的教学医院。麻省总医院出过11位诺贝尔奖得主，麻省总院是美国最大的研究型医院，每年投入研究的经费高达7.86亿美元。
Ether Dome简介：
因为近代世界第一例麻醉下的手术在此完成并公开演示，让Ether Dome闻名于世。当时William Morton医生给予以患者乙醚吸入麻醉，外科医生John Collins Warren（麻省总医院、哈佛医学院及New England Medical Journal创始人之一）完成手术。术后Warren询问患者感觉如何，在得到患者一再重复没有什么疼痛的感觉确认后，Warren医生转身，说出了那句被写进医学历史的著名的话：先生们，这不是谎话（"Gentlemen, this is no Humbug".）在Ether Dome还陈列了当时做手术的器具、乙醚瓶，还陈列了来自古埃及底比斯的木乃伊。

Prof. Weiyun SHI was invited to share the experience in clinical application of the bioengineered cornea initiated in China with the world in the Massachusetts General Hospital

On October 12, 2016, Prof. Weiyun SHI, the director of Shandong Eye Institute, president of Shandong Eye Hospital and leader of the Corneal Disease Group of Ophthalmological Society of Chinese Medical Association, was invited by the Massachusetts General Hospital Chinese Scientists and Staff Association (MGHCSSA) to give a speech on the development and clinical application of the bioengineered cornea in the Ether Dome of Bulfinch building at Massachusetts General Hospital (MGH). Experts and scholars all over the world have come and listened to the speech carefully. Questions raised by the audience have been answered by Prof. SHI in detail.

The wonderful speech delivered by Prof. SHI has led the attention of experts from all over the world to the flourishing Chinese ophthalmology. Prof. SHI delivering a speech in MGH shows that the application of the research achievements with proprietary intellectual property rights by Chinese ophthalmologists has been recognized by one of the world-top universities.

There are about 4 million corneal blindness cases in China. However, due to the shortage of corneal donors, fewer than 10,000 patients have the opportunity to undergo corneal transplantation each year. Most of the corneal blindness patients are waiting to see the light again in dark. The first bio-engineered cornea in the world, developed cooperatively by the team led by Prof. SHI (President of Shandong Eye Hospital) and Academician Lixin XIE and China Regenerative Medicine International Limited, has obtained the Registration Certificate for Medical Device from CFDA at the end of April, 2015 and was officially put into production and market on May, 23, 2015. As the world's first bio-engineered cornea, it can greatly alleviate the clinical situation of low cornea donation rate in China, and bring the hope of regaining sight for 4 million corneal blind patients in China. The world's first bioengineered corneal clinical transplantation conducted at Shandong Eye Institute (Qingdao Eye Institute, Shandong Eye Hospital) in September 2015 was successful.

The bioengineered corneas are made from xenogeneic corneas through multilevel processing using decellularized special techniques, which remove antigens in corneas like cells, impure protein and polysaccharide and preserve the structure of natural corneal stromal collagens and their transparency. The biocompatibility is good and the biosecurity is high. They can integrate into the surrounding tissue quickly. With transparent transplanted cornea, the visual acuity of patients can be improved quickly. This is an epoch-making high-tech production with completely independent intellectual property rights. As an important part of the achievements of the team, this project has also contributed to the winning of the Second Prize of 2015 National Science and Technology Progress Award.

To gain better clinical results in the clinical application of the world’s first bioengineered cornea, China Regenerative Medicine International Limited established the first doctor training base for bio-engineered corneal transplantation at Shandong Eye Hospital. Up to now, 246 domestic and international ophthalmologists have been trained here.

The successful application of the world's first bioengineered cornea has caught the world’s attention. Before the departure for America, Prof. SHI accepted an exclusive interview with Columbia Broadcasting System on details of the first bioengineered cornea at Shandong Eye Hospital. 

Prof. SHI, a member of the Standing Committee of Chinese Medical Association and the leader of the Corneal Disease Group of Ophthalmological Society, is one of the leaders in keratopathy in China. He has been engaged in ophthalmology clinical work, scientific research and teaching for 30 years, and is one of the few experts that have completed more than 10 thousand corneal surgeries in the world. He has not only brought benefits to countless patientsclinically,but also made great innovations academically. Focusing on the two major problems—shortage of donor corneas and poor diagnosis and treatment techniques, Prof. SHI has conducted innovative research to find therapeutic methods that are more suitable for Chinese patients. Some of his research achievements have been applied throughout the country.

Brief Introduction to MGH:

Founded in 1811, MGH is the third-oldest general hospital in the United States, and also the original and largest teaching hospital of Harvard Medical School and biomedical research facility located in the West End neighborhood of Boston, Massachusetts. It is also a major research hub, with an annual research budget of more than $786 million. 

Brief Introduction to Ether Dome:

The Ether Dome is a surgical operating amphitheater in the Bulfinch Building at Massachusetts General Hospital in Boston. It served as the hospital’s operating room from its opening in 1821 until 1867. It was the site of the first public demonstration of the use of inhaled ether as a surgical anesthetic on October 16, 1846. The Ether Dome event occurred when William Thomas Green Morton, a local dentist, usedetherto anesthetize Edward Gilbert Abbott. John Collins Warren, the first dean of Harvard Medical School, then painlessly removed part of a tumor from Abbott's neck. After Warren had finished, and Abbott regained consciousness, Warren asked the patient how he felt. Reportedly, Abbott said, "Feels as if my neck's been scratched". Warren then turned to his medical audience and uttered: "Gentlemen, this is no Humbug". The surgical instruments, the ether inhaler, and an Egyptian mummy are displayed in the Ether Dome.